Galixir

Galixir, established in Beijing in 2019, operates at the intersection of artificial intelligence and pharmaceutical research, positioning itself as a technology-driven partner for the drug development industry. The company was co-founded by CEO Dr. Chengtao Li, who holds a Ph.D. in Computer Science from the Massachusetts Institute of Technology (MIT). His background includes research at MIT and internships at Microsoft Research, providing a foundation in advanced computational methods that directly informs the company's core technology.

Galixir's business model is centered on accelerating the preclinical phase of drug discovery for its clients, which include pharmaceutical companies and research institutions. By employing its proprietary AI platforms, the company aims to significantly shorten the typical multi-year timeline for identifying and optimizing drug candidates. This is achieved through a B2B service model where Galixir collaborates on developing pipelines for various diseases, including autoimmune disorders, central nervous system diseases, cancers, and respiratory illnesses. Revenue is generated by providing these AI-driven services—from target identification to candidate validation—to partners, helping them reduce R&D costs and improve the probability of successful drug launches.

The core of Galixir's offering is its proprietary end-to-end drug discovery platform, Pyxir®. This platform integrates deep learning models with principles from computational and medicinal chemistry to automate and optimize key processes. Pyxir® encompasses several modules for tasks like generating novel molecular structures, predicting compound properties and toxicity, and analyzing patentability. A key component is TankBind, a deep learning framework developed by Galixir to predict how a small-molecule drug will bind to a protein. The company has demonstrated the platform's efficacy by identifying multiple drug candidates with high potency, verified through subsequent wet-lab experiments. In a notable 2022 milestone, Galixir announced a preclinical candidate for an autoimmune disease that was selected from approximately 80 compounds via the Pyxir® platform.

Keywords: AI drug discovery, preclinical R&D, computational chemistry, medicinal chemistry, Pyxir platform, drug candidate optimization, small molecule drug development, deep learning in pharma, pharmaceutical partnerships, Chengtao Li, TankBind, autoimmune disease therapeutics, oncology drug discovery, CNS drug discovery, drug property prediction